Live feed10:30:00·733dPRReleasevia QuantisnowIMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trialByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care
